Abstract Purpose: Extra domain B (ED-B) fibronectin is a specific tumor matrix marker for targeting angiogenesis in solid tumors. In this study, the radiotherapeutic potential of the directly radioiodinated divalent anti-ED-B antibody fragment, L19 small immunoprotein (L19-SIP; 75,000 Da), was compared with a pretargeting approach using the bispecific antibody AP39xm679 (bsMAb; 75,000 Da). Experimental Design: The bsMAb was prepared by coupling an anti-ED-B single-chain Fv (AP39) to the Fab ¶ of the murine antibody m679, which binds to the small peptidic hapten histamine-succinyl-glycine (HSG). As an effector molecule for the pretargeting approach, the 111
In-labeled peptide was significantly higher than 125 I-L19-SIP over 7 days. At the calculated maximally tolerated dose for each agent (with the kidney being the dose-limiting organ for pretargeting and the bone marrow for direct targeting), a mouse tumor dose of146 Gy could be given by pretargeting versus 45 Gy delivered by the direct approach. Radioimmunotherapy, the systemic administration of radioisotope-labeled tumor-targeting monoclonal antibodies (MAb), has been successful as a treatment for certain types of non -Hodgkin's lymphoma but has had little success in the treatment of most solid tumors (1) . This is due to the fact that, at maximally tolerated doses, radioimmunotherapy is not able to deliver a sufficiently high enough radiation dose to have a significant effect on the growth of solid tumors especially when applied as a monotherapy. In radioimmunotherapy, the hematologic toxicity caused by the high and long-lasting blood activities of MAbs is dose limiting. This is due to the continuous source of radiation to the highly radiosensitive red marrow. To overcome this limitation of directly radiolabeled IgG MAbs, enzymatic fragmentation or genetic engineering has been used to create constructs that clear rapidly from the blood and achieve maximum tumor accumulation more rapidly than a full-size MAb. Although the tumor-toblood ratios can be improved significantly with these constructs because of their faster clearance from the blood, both the total amount of radioactivity delivered to the tumor as well as the tumor residence time are decreased (2) . Thus, the advantage of being able to administer higher activities is offset by a decreased total tumor dose. This is especially true when MAbs, fragments thereof, are radiolabeled with radiometals or lanthanides because the bifunctional chelators needed for labeling become trapped in the proximal tubules of the kidney, leading to unwanted and high radiation doses to this organ that often are higher or equal to the tumor doses achieved (3) .
One approach to overcome the limitations posed by direct radiolabeling of MAbs or their smaller fragments/constructs is the use of pretargeting (4, 5) . The pretargeting systems solve the slow blood clearance problem by attaching the radionuclide to a very small compound that is characterized by rapid body elimination via renal clearance (f80% of the injected activity excreted in the urine within 1-2 hours in mice).
Moreover, these small molecules are able to quickly extravasate and diffuse to their tumor targets very efficiently. Because of their rapid diffusion and kidney elimination, these small molecules need to be very tumor selective and their specific targeting needs to occur with a high affinity, which can be achieved, for example, by making use of biotin/avidin binding, hapten/antibody binding, or the complementary oligonucleotide recognition systems (6) . In this study, we used a bispecific Mab (bsMAb), consisting of one binding moiety specific for the angiogenesis-associated target, extra domain B (ED-B) fibronectin, and the other specific for a small hapten that can be radiolabeled either with 111 In or 90 Y after attachment of a bifunctional chelator. The unlabeled bsMAb is given first and allowed to accumulate in the tumor. Subsequently, the rapidly clearing radiolabeled hapten is injected. The interval between the bsMAb targeting and the subsequent injection of the radiolabeled compound is dependent on the blood clearance properties of the bsMAb and has to be optimized. If given too soon, a sizable fraction of the radiolabeled hapten-peptide binds to the bsMAb in the blood, slowing its clearance from the circulation. This type of pretargeting also benefits from the use of bivalent haptenpeptides, which greatly increase tumor uptake and retention, a mechanism known as the ''affinity enhancement system'' (7). High cure rates can be achieved by pretargeted radioimmunotherapy in mice bearing human colon carcinoma xenografts, significantly improving therapeutic responses if compared with directly radiolabeled IgG or F(ab ¶) 2 (8 -13) . In addition, Kraeber-Bodere et al. (14) have shown that repeated pretargeting applications increase the therapeutic efficacy without increasing its systemic toxicity in a human medullary thyroid cancer mouse model and that pretargeted radioimmunotherapy can be used with paclitaxel combination therapy to further improve efficacy in this animal model.
The fibronectin splice variant B (ED-B) is considered a panspecies angiogenesis-associated tumor matrix marker that is expressed in close proximity to the tumor neovasculature and in the stroma of a large variety of hyperplastic and neoplastic tissues. It is also expressed in healthy tissues during angiogenic processes (15) . The completely human anti-ED-B single-chain Fv (scFv) MAb fragment L19 with a subnanomolar affinity has been generated (16) . Derivatives of scFv L19 have been applied successfully in different strategies for tumor imaging and therapy in both animal models (17 -19) as well as in patients for immunoscintigraphic detection of primary tumors and their metastases (20) . ED-B is considered to be a promising target for radioimmunotherapy of solid tumors because, being a matrix antigen expressed in close vicinity of new tumor vessels, it is rapidly accessible via the circulation, and its relationship to the angiogenic processes in the tumor might facilitate selective destruction of tumor vasculature (21) .
Berndorff et al. (21) recently examined three derivatives of the L19 anti-ED-B MAb (i.e., a 50,000-Da scFv, the 75,000-Da small immunoprotein (SIP), and the 150,000-Da IgG) radiolabeled with 90 Y or 131 I and determined that 131 I-L19-SIP had the most favorable biodistribution properties and superior antitumor effects compared with the other radiolabeled derivatives investigated. L19-SIP is a divalent scFv fusion protein encoding an IgE C H 4 domain for dimerization (21) . To investigate the potential of the pretargeting system in combination with the ED-B tumor matrix marker, scFv AP39 (derived from scFv L19) was used to form a bsMAb with the murine anti -histamine-succinyl-glycine (HSG) 679 Fab ¶ (AP39xm679; Fig. 1 ). As a hapten, 111 In-labeled HSG was used. For subsequent in vivo characterization, the human glioblastoma xenograft model U251 was chosen. In this tumor model, ED-B expression can be detected in the perivascular space as well as in the stroma. 6 The kinetics of both the iodinated bsMAb as well as the 111 In-labeled HSG hapten were investigated in mice bearing human glioblastoma xenografts (U251) and compared with the kinetics and tumor accumulation of the radioiodinated L19-SIP.
Materials and Methods
Antibody derivatives. scFv AP39 was generated by insertion of the peptide sequence (Gly) 3 -Cys-Ala at the COOH-terminal end of the V L chain of the scFv L19. Expression in Pichia pastoris and product purification were done according to Cunha et al. (22) . Briefly, the AP39-encoding DNA sequence was cloned into the P. pastoris expression vector pPIC9K (Invitrogen, Carlsbad, CA). This construct contains a methanol-inducible promoter (AOX1) and a signal sequence (from yeast a factor) for expression and secretion of the recombinant product. Stably transfected yeast clones (based on strain GS115) were established by electroporation and subsequent antibiotic selection. The clones were cultivated at 30jC in buffered minimal glycerol-complex medium or basal mineral medium, and methanol was added for promoter induction during the expression phase. The recombinant product had a correctly processed terminus and high antigen-binding activity. AP39 was purified from culture supernatant by protein A affinity chromatography and size exclusion chromatography followed by Tris (2-carboxy-ethyl)-phosphin-HCl treatment (for reduction of covalent dimers).
The purified AP39 forms a noncovalent dimeric scFv molecule (M r f50,000 Da). L19-SIP is a 75,000-Da SIP that was expressed in mammalian cells and purified by immunoaffinity chromatography as described earlier (23) . Different L19-based MAb formats have been shown to have similar binding affinities when measured in solution to avoid avidity effects, but when the antigen is bound to a solid phase, these bivalent L19-based formats show better performance due to slow disassociation rates (24) .
The murine anti-HSG IgG (m679) was purified from tissue culture medium by protein A and ion exchange chromatography. The F(ab ¶) 2 was prepared by pepsin digestion. The AP39xm679 bsMAb was made by cross-linking reduced sulfhydryl groups with N,N ¶-1,2-phenylenedimaleimide (PDM; Aldrich, Milwaukee, WI). Briefly, AP39 and 679 F(ab ¶) 2 were both reduced with 2 mmol/L Tris (2-carboxy-ethyl)-phosphin-HCl (Pierce, Rockford, IL) in 0.1 mol/L phosphate buffer (pH 7.4) for 30 minutes at 37jC. The reduced proteins (AP39-SH and 679 Fab ¶-SH) were dialyzed into coupling buffer [50 mmol/L sodium acetate, 0.5 mmol/L EDTA (pH 5.0)]. AP39-SH was then derivatized with a 500-fold molar excess of PDM by adding an aliquot of 20 mmol/L PDM (prepared in 90% N,N ¶-dimethylforamide) to a final concentration of 4 mmol/L. After 30 minutes at room temperature, the reaction mixture was dialyzed into coupling buffer to remove unreacted PDM. AP39-PDM was then combined with 679 Fab ¶-SH at a molar ratio of 1.5:1 and, after 90 minutes at room temperature, was quenched with 10 mmol/L cysteine. The solution was adjusted to pH 7.0 with Na 2 HPO 4 .
The resulting AP39xm679 Fab conjugate was purified using two affinity chromatography steps. Affinity chromatography with IMP-291-Affigel (25) , which binds 679 MAb, removed unreacted AP39-PDM. The IMP-291-purified material was further purified using protein A agarose, which specifically binds AP39 but not 679 Fab ¶ and removes unreacted 679 Fab ¶. Purity of the material was determined by size exclusion high-pressure liquid chromatography (HPLC) and SDS-PAGE, whereas the bispecific binding of the AP39xm679 bsMAb was determined by BIAcore analysis.
Radiolabeling of antibodies and HSG-hapten-peptide. Radioiodinanation was done following a slightly modified version of the original Iodo-Gen method (26) using Iodo-Gen precoated iodination tubes (Pierce). Briefly, 200 Ag (L19-SIP) or 280 Ag (AP39xm679 bsMAb) of protein in 500 AL PBS were labeled with 0.5 mCi of Na 125 I (Amersham Biosciences, Little Chalfont, United Kingdom). After incubation at room temperature for 10 minutes, the radiolabeled protein was separated from free radioiodine by gel filtration using NAP5 columns (Amersham Biosciences, Upssala, Sweden) that were pretreated with 0.5% bovine serum albumin in PBS and equilibrated and eluted with PBS.
Each radiolabeled protein was tested for purity and immunoreactivity before its use. Size exclusion HPLC was done using a TSK-gel column SWxL, 300 Â 7.8 mm (Tosoh Haas, Montgomeryville, PA), with TSK buffer (0.1 mol/L Na 2 HPO 4 , 0.1 mol/L Na 2 SO 4 , 0.05 mol/L NaN 3 ) as the mobile phase and a flow rate of 0.5 mL/min.
The immunoreactivity of the radioimmunoconjugates was determined using a test column composed of a Pasteur pipette filled with 250 AL ED-B Sepharose resin (27) and saturated with 0.5% bovine serum albumin in PBS. The test column was loaded with f0.2 MBq radiolabeled protein in 500 AL of 0.5% bovine serum albumin in PBS and rinsed with 2 Â 500 AL of 0.5% bovine serum albumin in PBS to remove the nonimmunoreactive fraction. The immunoreactive fraction was then eluted with 2 Â 750 AL of aqueous triethylamine solution (0.1 mol/L). The radioactivity of the fractions and that remaining on the column was measured with a dose calibrator. The immunoreactive fraction was expressed as the percentage radioactivity bound to the column. After purification, the concentration of AP39xm679 bsMAb was determined by measurement of the absorbance of the sample with an UV spectrometer, and the specific activity needed for the biodistribution studies was adjusted by addition of nonlabeled protein.
The hapten-peptide used in these studies was the divalent HSG- In-labeled IMP-241 (1.5 Â 10 À11 mol, 296 kBq). After the animals were anesthetized and sacrificed by decapitation (at the indicated time points), the dissected organs and collected excretions were counted for radioactivity as described above for the nonpretargeted studies.
Mouse dosimetry. Self-to-self doses for mouse organs were estimated based on medical internal radiation dose (29) (21) . About the dose-limiting organ, which was either the red marrow (directly targeted L19-SIP) or the kidneys (pretargeted peptide-hapten), maximum activities to be injected per mouse were determined based on published human tolerance doses of TD 5/5 = 2.5 Gy for the red marrow and TD 50/5 = 20 Gy for the kidneys (30) . These maximum tolerated activities per mouse were used to calculate absolute tumor doses (in Gy) for a 100 mg normalized tumor mass in relation to the respective dose-limiting organ (therapeutic index).
Results
Characterization of the AP39xm679 bsMAb. The affinitypurified preparation of AP39xm679 bsMAb was shown by size exclusion HPLC ( Fig. 2A ) to consist of a major peak at 8.89 minutes corresponding to the expected molecular size of f75,000 Da, an ascending shoulder at 8.11 minutes, and a minor peak at 10.36 minutes. A buffer peak at 11.44 minutes was also observed. Surface plasmon analysis (BIAcore) indicated that the purified AP39xm679 contained binding specificities for both HSG and ED-B (Fig. 2B and C) .
Radiolabeling of antibodies and HSG-hapten-peptide. The radiochemical yield of the radioiodinations ranged between 60% and 90%, and the radiochemical purity, as determined by size exclusion HPLC, was always >80% with <5% of free iodide. For all iodinated proteins, the immunoreactivity was >80%. The radiochemical purity of the 111 In-labeled haptenpeptide, as determined by instant TLC and reversed-phase HPLC, was always >90% with no free 111 In in the samples.
Biodistribution of 125 I-labeled AP39xm679 bsMAb and L19-SIP in tumor-bearing mice. The biodistribution and pharmacokinetic data for the 125 I-labeled AP39xm679 bsMAb compared with the L19-SIP in tumor-bearing mice are shown in Tables 1  and 2 Both products cleared rapidly from the blood, with f1.3% ID/g in the blood 1 day after their injection and with maximum tumor accumulation occurring at 4 hours after injection and with similar uptake (averaging between 17% and 20% ID/g) and retention. These data suggest that the bsMAb retained its ability to target ED-B as well as L19-SIP did, with similar pharmacokinetic properties.
The different specific activities of the radiolabels of the 125 I-AP39xm679 used for the initial investigation of biodistribution and for monitoring of the bsMAb in the pretargeting experiments did not significantly affect biodistribution and tumor uptake (data not shown).
AP39xm679-pretargeted 111 In-hapten-peptide. Previous experience with bsMAb pretargeting systems, including bsMAbs based on the 679 anti-HSG MAb, suggested that optimal pretargeting results can be obtained when (a ) 10-fold more moles of the bsMAb are given compared with the moles of radiolabeled hapten-peptide to be injected, (b) the A, size exclusion HPLC of purified AP39xm679 bsMAb showing the product as a major peak with a molecular size of f80 kDa. B, BIAcore analysis examining the binding of the bsMAb to a HSG-peptide chip. Once the material was bound, ED-B was injected to determine the presence of functional AP39. Although both the protein A^bound and flow-through fractions bound to the HSG chip, only the protein A^bound fraction was also able to bind ED-B, indicating bispecific-binding properties. C, ED-B was injected and allowed to bind to a Ni-NTA chip, and after a 90-second wash, either AP39xm679 bsMAb or AP39 scFv was injected. Both products had similar ED-B-binding properties.
I-AP39xm679 bsMAb indicated that the 111 In-hapten-peptide should be given between 24 and 48 hours after the bsMAb injection (Table 1) . Therefore, two different groups of mice were examined, one where the 111 In-hapten-peptide was given at 25 hours and the other at 41 hours. In both cases, the molar ratio of bsMAb to peptide was 10:1. Biodistributions in tumor-bearing mice were carried out up to 168 hours after injection of the radiolabeled hapten-peptide.
The tumor and tissue uptake and clearance for the pretargeted 111 In-hapten-peptide using the two intervals tested, along with the data for the 125 I-L19-SIP, are shown in Tables 2  and 3A Inhapten-peptide was efficiently cleared from the body through the urine, whereas only a small fraction was found in the feces (Tables 3A and B and 4) .
In addition to the uptake seen in tumors, the ovaries and the uterus showed an increased uptake of pretargeted 111 In-haptenpeptide (Table 3A and B) . Similarly, both the bsMAb and the L19-SIP showed an enhanced uptake in these tissues (Tables 1  and 2 ).
In contrast to pretargeting settings, the uptake of 111
Inhapten-peptide alone in tumor and normal tissue (including ovaries and uterus) was rather low (Table 4) . NOTE: Total excretion is measured cumulatively at indicated time points and is calculated as % ID. All data are presented as mean and SD (n = 3). In-hapten-peptide and 125 I-L19-SIP, the self-to-self organ doses in mice were estimated for the respective therapeutic radioisotopes 90 Y and 131 I, respectively. The highest calculated dose levels can be observed in tumor as well as in ovaries and uterus. Pretargeting the tumors with AP39xm679 using either a 25-hour or a 41-hour clearance time yielded a much higher radiation dose to the tumors if compared with the directly targeted L19-SIP (2,568 and 2,278 mGy/MBq for the 25-hour and 41-hour clearance times, respectively, versus 939 mGy/ MBq for L19-SIP). The increased dose levels in both uterus and ovaries are consistent with known ED-B expression in these organs (32) . The radiation doses for the other investigated tissues and organs were comparable in the pretargeting and the directly radiolabeled L19-SIP groups (data not shown).
In contrast to 131 I-L19-SIP, where the red marrow was the dose-limiting organ when related to the human tolerance dose (TD 5/5 = 2.5 Gy), for the pretargeted 90 Y-hapten-peptide the kidneys were the dose-limiting organ (TD 5/5 = 20 Gy). It was calculated that 59 MBq (25-hour clearance interval) and 57 MBq (41-hour clearance interval) of AP39xm679-pretargeted 90 Y-hapten-peptide could be injected per mouse to achieve this maximally tolerated kidney dose (Fig. 4) . This maximum tolerable activity would result in a tumor dose of 146 and 134 Gy, respectively. For 131 I-L19-SIP, the corresponding maximum tolerable activity per mouse was 48 MBq, resulting in a tumor dose of 45 Gy (Fig. 4) . The ratio between the U251 tumor (100 mg) and the dose-limiting organ was defined as the therapeutic index and was higher for 131 I-L19-SIP (index value, 18) if compared with the AP39xm679-pretargeted 90 Y-hapten-peptide (index value, f7 for both investigated clearance intervals).
Discussion
In this report, the radiotherapeutic potential of two different techniques, (a) direct targeting of the radioiodinated, divalent L19-SIP and (b) a two-step pretargeting method, was compared in a human glioblastoma xenograft mouse model. Both MAb constructs target ED-B fibronectin, a stromal tumor marker strongly associated with neovascularization. A novel bsMAb pretargeting system that uses an anti-HSG-HSG-peptide secondary recognition system was used because this is highly flexible and has the potential to target a variety of compounds (28) . Because bsMAb can be fully humanized, these pretargeting agents would be less immunogenic than those using streptavidin. In most instances reported in the literature, bsMAbs are commonly prepared from Fabs or IgGs, but our results clearly indicate that chemical combinations of a Fab ¶ and a modified scFv (using an additional unpaired cysteine residue) can lead to the efficient generation of a functional bsMAb. Importantly, this bsMAb showed high tumor retention over a 3-day period, while at the same time quickly clearing from the blood and nontumor tissues. Good tumor retention and the fast blood clearance are highly favorable properties for a bsMAb to be used as a pretargeting tool. 111 In-labeled HSG-peptide, when used for pretargeting, showed a rapid and high (f17% ID/g) tumor uptake that rivaled that of the 125 I-labeled L19-SIP, but tumor retention was longer with the pretargeted peptide. The enhanced retention most likely reflects the use of a radiometal-labeled pretargeted peptide, whereas the directly radiolabeled MAb was radioiodinated. Radiometal-labeled MAbs frequently have a longer retention in tumors than radioiodinated forms because radioiodinated MAbs can be dehalogenated, or when internalized and catabolized, radioiodine will be quickly eliminated from the cell, whereas radiometals are retained (33) .
131 I-L19-SIP was used because earlier studies had indicated that renal uptake of 111 In-L19-SIP was f2-fold higher than tumor uptake for this agent, with dosimetry data indicating unfavorable tumor-tokidney ratios for 90 Y-L19-SIP (21 Lu (8, 28, 34) , and in each instance, excellent tumor-to-nontumor ratios, even tumor-to-kidney ratios, were reported.
Previous studies suggested that the concentration of bsMAb in the blood needed to be V1.0% ID/g to facilitate optimal pretargeting (31) . Therefore, we investigated two different clearance intervals in the U251 tumor model, 25 and 41 hours, which, based on the clearance of the AP39xm679 bsMAb, suggested blood concentrations of approximately 1.4% and 0.4% ID/g (i.e., at 24 and 48 hours, respectively). Regardless of the interval at which the 111 In-hapten-peptide was given, tumor uptake and the total amount of radioactivity delivered to the tumor at an estimated maximum tolerated dose were similar. I-L19-SIP (C). For each particular radioimmunoconjugate, the dose delivery is shown for the respective dose-limiting organ (atTD 5/5 ) and for a tumor mass of 100 mg.
